Core C - Modeling Core
Core C - Modeling Core
批准号:
10551582
负责人:
Adolfo Garcia-Sastre
金额:
$18.94万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-01-20 至 2027-12-31
关键词:
AffectArtificial IntelligenceBenignBioinformaticsBiological ProcessCOVID-19COVID-19 severityCessation of lifeChiropteraClinicalCollaborationsCoronavirusDataData SetDevelopmentDiseaseDisease MarkerDisease OutcomeEventGenesGenetic TranscriptionHospitalizationHumanImmune responseInfectionInflammatoryInnate Immune ResponseMissionModelingMolecularMusNetwork-basedOutcomePathogenicityPathway interactionsPlayPopulationPreventive MedicineProcessSARS coronavirusSARS-CoV-2 infectionSARS-CoV-2 variantScientistSeveritiesSeverity of illnessSymptomsSystems BiologyTechnologyTissuesTropismVaccinationValidationVariantViralVirusVirus Replicationcoronavirus diseasedata managementheuristicshuman dataimprovedin vivolensmembernetwork modelsnew therapeutic targetnext generationnovelnovel therapeutic interventionpathogenpredictive markerpredictive modelingpredictive signaturetherapeutic targetthree dimensional structurevirus host interactionvirus tropism
中文摘要
项目摘要/摘要
SARS-CoV-2感染导致不同的临床结局,从轻微的症状到
住院治疗,有时甚至死亡。然而,预测COVID-10疾病结局的生物标记物
(即症状严重程度、病毒复制),这对预防医学来说是关键的,但尚未
已确认身份。重要的是,阐明支配预测签名的分子成分
临床结果将提供重要线索,指导开发新的治疗方法
战略。这款U19将建立在前一代FluOMICS下一代产品收集的大量数据基础上
科学家和追寻两个趋同的假说1)宿主先天免疫反应通路被触发
由SARS-CoV-2感染决定新冠肺炎病的致病结局2)串扰
SARS-CoV-2变异株和这些宿主固有途径之间导致不同的转录和
翻译后特征导致疾病严重程度和宿主趋向性的差异
病毒。建模核心的主要目标将是使用基于网络的建模方法
整合项目1和项目2产生的实验数据,识别先天生物
可以预测新冠肺炎疾病结果并在协作中进行功能验证的流程
项目1和项目2。在目标1中,建模核心将集成
项目1来自人体体内和小鼠体内研究的数据,并由
技术核心、数据管理和生物信息学核心。建模核心将构建主机
描述新冠肺炎早期事件中病毒与宿主相互作用的响应网络模型
感染和疾病,即病毒复制,在自然情况下逃避宿主的先天免疫反应
在接种疫苗和触发有害的促炎免疫反应时。在……里面
目标2,建模核心将对项目1应用启发式方法和迭代过程
项目2.这种方法将有助于确定宿主-病原体相互作用下游的新途径。
重要的是,它将指导项目2中这些基因和途径的基因编辑的实施
通过实验验证这些模型并提高它们的准确性;这将有助于理解SARS是如何-
CoV-2变种影响AIM 1内置的病毒-宿主网络。在AIM 3中,建模核心将使用
通过实验确定了病毒-宿主相互作用的3D结构和一个人工智能模型,
AlphaFold,以确定冠状病毒的自然宿主蝙蝠中的病毒与宿主的相互作用,以及
将它们与人类的相互作用进行比较,以研究病毒的宿主取向并推断这些变化是如何发生的
可能会对感染的致病结局产生影响。总而言之,建模核心将提供
将指导识别和实验验证新的可用药靶标的平台
阻止病毒在受感染的宿主和世界各地的人群中传播。
英文摘要
PROJECT SUMMARY/ABSTRACT
SARS-CoV-2 infection leads to different clinical outcomes that range from mild symptoms to
hospitalization and sometimes death. However, biomarkers predictive of COVID-10 disease outcomes
(i.e., symptoms severity, viral replication), which are key for preventive medicine, have not yet been
identified. Importantly, elucidation of the molecular components that govern predictive signatures of
clinical outcomes will provide important clues that will guide the development of novel therapeutic
strategies. This U19 will build on a wealth of data gathered by the previous FluOMICS next-generation
scientist and pursue two converging hypotheses 1) host innate immune response pathways triggered
by SARS-CoV-2 infection determine the pathogenic outcome of COVID-19 disease 2) the crosstalk
between SARS-CoV-2 variants and these host innate pathways results in different transcriptional and
post-translational signatures contributing to the difference in disease severity and host-tropism of the
viruses. The primary objective of the Modeling Core will be to use network-based modeling approaches
to integrate the experimental data generated by Project 1 and Project 2, identify innate biological
processes that can predict COVID-19 disease outcomes and validate them functionally in collaboration
with Project 1 and Project 2. In Aim 1, the Modeling Core will integrate OMIC datasets generated in
Project 1 from data from Human in vivo and mice in vivo studies and processed and analyzed by the
Technology Core and the Data Management and Bioinformatics Core. The Modeling core will build host
response network models that depict the viral-host interaction at play in early events of COVID-19
infection and disease, i.e., viral replication, escape from the host innate immune response in natural
infection and upon vaccination and triggering of the deleterious pro-inflammatory immune response. In
Aim 2, the Modeling Core will apply heuristic approaches and an iterative process with Project 1 and
Project 2. This approach will help identify novel pathways downstream of host-pathogen interactions.
Importantly, it will guide the implementation of gene editing of these genes and pathways in Project 2
to validate these models and improve their accuracy experimentally; It will help understand how SARS-
CoV-2 variants affect the viral-host networks built-in Aim 1. In Aim 3, the Modeling Core will use
experimentally identified 3D structures of viral-host interactions and an artificial intelligence model,
AlphaFold, to identify virus-host interaction in the bat, the natural host of the coronaviruses, and
compare them to interactions in humans to study host-tropism of the virus and infer how these changes
could impact on the pathogenic outcome of the infection. Altogether the Modeling core will provide a
platform that will guide the identification and experimental validation of novel druggable targets that can
stop the spread of the virus in infected hosts and worldwide populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A deep longitudinal analysis of next generation influenza vaccines in older adults
-
批准号:10544172
-
项目类别:
-
资助金额:$219.59万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Immune phenotyping of responses to influenza virus vaccination and infection
-
批准号:10595642
-
项目类别:
-
资助金额:$21.69万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
In vivo virology core
-
批准号:10512625
-
项目类别:
-
资助金额:$376.07万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Admin-Core-001
-
批准号:10710092
-
项目类别:
-
资助金额:$12.01万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
A deep longitudinal analysis of next generation influenza vaccines in older adults
-
批准号:10342393
-
项目类别:
-
资助金额:$162.26万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Immune phenotyping of responses to influenza virus vaccination and infection
-
批准号:10435237
-
项目类别:
-
资助金额:$28.32万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Development of CoV inhibitors against non-enzymatic targets
-
批准号:10514327
-
项目类别:
-
资助金额:$512.2万
-
财政年份:2022
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
-
批准号:10222305
-
项目类别:
-
资助金额:$396.84万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
-
批准号:10706729
-
项目类别:
-
资助金额:$12.01万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
-
批准号:10688370
-
项目类别:
-
资助金额:$204.42万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Core G - IOF Management Core
-
批准号:10153663
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
-
批准号:10855044
-
项目类别:
-
资助金额:$327.19万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization
-
批准号:10688382
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization
-
批准号:10222310
-
项目类别:
-
资助金额:$87.85万
-
财政年份:2020
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
-
批准号:10066306
-
项目类别:
-
资助金额:$115.35万
-
财政年份:2019
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
-
批准号:10534661
-
项目类别:
-
资助金额:$112.69万
-
财政年份:2019
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
-
批准号:10318120
-
项目类别:
-
资助金额:$112.69万
-
财政年份:2019
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses
-
批准号:9625439
-
项目类别:
-
资助金额:$145.01万
-
财政年份:2019
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
Core A - Administrative Core
-
批准号:10080701
-
项目类别:
-
资助金额:$35.81万
-
财政年份:2018
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)
-
批准号:10551578
-
项目类别:
-
资助金额:$265.15万
-
财政年份:2018
-
负责人:Adolfo Garcia-Sastre
-
依托单位:
海外基金